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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A4044 courses, and 760 (1.5%) received 5 courses or more. The time from
diagnosis to when 50% of the subset received TKR was signiﬁcantly
longer (p1 year, an average of 9 months longer than those with no IA
HA. Patients who received 5 courses had a delay in TKR by 3.6 years.
Conclusions: Among 182,022 patients with knee OA, those who
received IA HA had a signiﬁcantly longer time before TKR. More courses
of IA HA injections were associatedwith a longer time toTKR. This study
suggests a signiﬁcant clinical beneﬁt from use of IA HA for OA as delay in
time to TKR can have important clinical and economic implications.Median Time from knee OA diagnosis to TKR by number of courses of IA HA
No IA HA 1 2 3 4 5þ
Days to TKR 114 386 648 875 1054 1312
Years to TKR 0.3 1.1 1.8 2.4 2.9 3.6675
EVALUATION OF THE CLINICAL EFFICACY OF AUTOLOGOUS
CONDITIONED SERUM IN PATIENTS WITH COXARTHROSIS
K. Shirokova, S. Noskov, L. Shirokova. Yaroslavl State Med. Univ.,
Yaroslavl, Russian Federation
Purpose: The aim of this open study was a comparative assessment of
the effectiveness of local therapy with autologous conditioned serum
(ACS) and low molecular weight hyaluronic acid (LHA) in patients with
coxarthrosis.
Methods: The study included 60 patients with ﬁrm coxarthrosis in
accordance with ACR criteria at the age of 55,5 ± 8,7. The main group
(ACS treatment) consisted of 33 (55%) persons. Experimental group
(LHA treatment) consisted of 27 patients who are comparable with the
main group patients in terms of age, BMI, radiographic stage, disease
duration and severity of clinical indicators. ACS was prepared in
accordance with established method and injected intraarticularly (2.5
ml twice a week for three weeks). LHA treatment consisted of 3 weekly
intraarticular injections of 40 mg sodium hyaluronate each. All intra-
articular actions were performed with ultrasound control. Treatment
efﬁciency was evaluated after 1,3 and 6 months after treatment, the
following criteria were used: bodily pain dynamics in accordance with
VAS, morning stiffness module and Womac index functional scale, and
Lequesne index. “Area under the curve” (AUC) approach with estima-
tion of treatment efﬁciency prolongation for 6 months (AUC6) was used
for evaluation of clinical effect retention.
Results: A decrease in pain syndrome intensity according to VAS in hip
joints at 1, 3 and 6 months of treatment in both compared groups was
recorded.However, a signiﬁcant regression was observed in the treat-
ment of pain with ACS in comparison with LHA.After 1 month the
decrease of pain severity in accordancewithVASwas comparable (9.1%, p
¼ 0.40), after 3 and 6 months, pain severity was higher in the LHA group
compared with ACS group (þ 52.5%, p ¼ 0.009 and þ 33.1%, p ¼ 0.047
respectively). AUC6 in case of ACS treatmentwas 35,6% (p¼ 0,011) higher
compared with LHA treatment. Extension of the clinical effectiveness
expressed via "morning stiffness" module of the Womac index AUC6
indicatorwas 55.9% (p¼0.003) higher in case of ACS treatment compared
with LHA treatment. Womac functional scale in case of ACS improved
through all three control timepoints (-23.1% -28.5% -39.1%; p ¼ 0.001).
Same dynamics was observed in LHA group as well (-35.6%, -26.4%; p ¼
0.001 and -20.4%; p ¼ 0.005), however after 6 months of monitoring
more signiﬁcant improvement of articular functionwas recorded within
ACS group compared with LHA (18.3%, p ¼ 0.044). The overall clinical
efﬁcacy in accordancewith Lequesne indexwith a six-monthmonitoring
was comparable in both groups, thedifference cameup to8,8% (p¼ 0,65).
Conclusions: Intensity of pain, stiffness, functional status and overall
clinical severity of coxarthrosis signiﬁcantly and consistently decreased
during therapy with ACS and LHA.However, favorable changes of local
therapy with LHAwere inferior in duration of conservation of treatment
effect of ACS.676
REFINEMENT OF PRECLINICAL STUDIES FOR
VISCOSUPPLEMENTATION THERAPY EVALUATION: INTEREST OF
COMPLEMENTARY TECHNIQUES TO EVALUATE CARTILAGE IN A
RABBIT MODEL OF EARLY OSTEOARTHRITIS
S. Kaderli y, E. Chereul z, E. Viguier x, T. Roger x, M. M€oller k,
L. Scapozza k, O. Jordan k, C. Boulocher x. y Sch. of Pharmaceutical Sci.,
Univ. of Lausanne and Geneva, Geneva, Switzerland; zVoxcan, Marcy
l'Etoile, France; xVetAgro Sup, campus veterinaire, Marcy l'Etoile, France;
k1Sch. of Pharmaceutical Sci., Univ. of Lausanne and Geneva, Geneva,
Switzerland
Purpose: One of the major challenges of the viscosupplementation (VS)
therapy is the development of more efﬁcient formulations and, to this
end, the use of animal models of osteoarthritis (OA) is still mandatory.
The assessment of VS efﬁcacy is challenging mainly since its structural
effects are subtle. In order to reﬁne preclinical VS efﬁcacy studies and
reduce the number of animals used, there is a crucial need for more
sensitive and discriminant evaluation tools. In this study, we especially
focused on complementary techniques to evaluate OA cartilage in a
rabbit model of early OA.
Methods: Cranial cruciate ligament transection (ACLT) was performed
in the left knee of white New-Zealand rabbits (n¼12) to induce trau-
matic OA. One week post-ACLT and then weekly for 5 weeks, the
operated knees of 6 rabbits were injected with a hyaluronic acid (HA)
containing commercial formulation (Ostenil®, HA group). One group
was injected with saline (operated-control group, n¼6). The con-
tralateral right knees (n¼8) were used as unoperated-controls. End-
point evaluation was done at the 6th week post-ACLT and included:
gross and histological scoring of cartilage lesions, measurement of
cartilage thickness by Equilibrium Partitioning Iodine Contrast micro-
Computed Tomography (EPIC m-CT) as well as the evaluation of the
surface by Scanning Electron Microscopy (SEM).
Results: Gross and histological scorings showed statistical differences
between operated and unoperated knees; however, no difference
between the HA and operated-control groups was evidenced. SEM
revealed that unoperated-control samples had normal smooth to rough
surfaces with discreet cable-like structures. Cartilage from the operated
knees presented rough surfaces and clearly visible cable-like structures,
which might be the sign of cartilage matrix erosion. Finally, mean car-
tilage thickness and volume measured by EPIC m-CT were comparable
for the 3 groups. Interestingly, the use of the thickness distribution
representation showed clear differences in the intact cartilage occur-
rences (i.e. thickness higher or equal to 0.9 mm). Indeed, intact cartilage
proportion decreased statistically from 20% in the unoperated-control
group to 10% in the operated-control group. In addition, intact cartilage
proportion in the HA treated knees was equivalent to unoperated-
control group, highlighting a moderate efﬁcacy of HA which was
detected neither by histology nor by SEM.
Conclusions:Complementary techniqueswere implemented toevaluate
cartilage lesions in a rabbitmodel of earlyOA in order to reﬁne preclinical
VS efﬁcacy studies. This study points out that classical evaluation tools
(macroscopy and histology) are sensitive enough to discriminate
between cartilage from unoperated and operated groups in early OA but
that EPIC-mCTalsopermits the detection of the subtle structural effects of
HA, validating this technique as a powerful evaluation tool.
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EVIDENCE OF IN VIVO DRUG DELIVERY VIA THE TAT PROTEIN
TRANSDUCTION DOMAIN
A. Hamil y, D. Haudenschild z, S. Dowdy y, R. June x. yUniv. of California,
San Diego, La Jolla, CA, USA; zUniv. of California, Davis, Sacramento, CA,
USA; xMontana State Univ., Bozeman, MT, USA
Purpose: Drug delivery to synovial joints is a major limitation for
developing effective treatments for osteoarthritis (OA). Synovial joint
anatomy includes large pores that allow direct transport between
synovial ﬂuid and fenestrated capillaries. This transport preferentially
selects larger molecules to remain within the joint and exports smaller
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A405molecules to circulation in order to maintain the high-viscosity needed
for efﬁcient lubrication by synovial ﬂuid. One example of this challenge
is that most contrast-enhanced clinical imaging protocols deﬁne carti-
lage defects by exclusion of systemically delivered small molecule
contrast agents. This architecture presents a challenge to effective drug
delivery for treating OA. We hypothesized that cationic TAT-PTDs
(Peptide Transduction Domains) would enable in vivo drug delivery
into synovial joints because of electrostatic attraction between the
cationic TAT PTD and anionic cartilage glycosaminoglycans.
Methods: To address our hypothesis, we utilized a non-invasive in
vivo model of post-traumatic OA. In this model, joints are subjected
to a single mechanical overload which results in upregulation of IL-6
mRNA. 24 hours prior to injury, we treated the animals with siRNA
complexed to a TAT-PTD fusion protein for delivery of siRNA. The
fusion protein, TAT PTD-DRBD (Protein Transduction Domain cou-
pled to a Double-stranded RNA Binding Domain), was complexed to
siRNA at a 1:8 molar ratio of siRNA to protein. Controls included
both untreated and off-target-treated joints. Therapeutic com-
pounds and controls were delivered via 12 mL injection to the
selected knee joint using a medial approach. Joints were injured by a
single mechanical overload applied at 500 mm/s which results in a
mid-substance tear of the ACL. Joints were harvested for qPCR 1
week after injury.
Results: Injury resulted in upregulation of IL-6 mRNA in the injured
knee joint relative to the uninjured contralateral knee. There was
signiﬁcantly less upregulation of IL-6 mRNA in injured joints treated
with the PTD-DRBD complexed to an anti-IL-6 siRNA (p ¼ 0.027,
Figure 1) while treatment treated with off-target siRNA complexes had
no effect.
Conclusions: These data demonstrate the feasibility of in vivo bioactive
drug delivery to synovial joints using the TAT Peptide Transduction
Domain, in this example for delivery of siRNA to attenuate injury-
induced expression of IL-6. Future studies may utilize TAT fusion pro-
teins as well as the PTD-DRBD to advance both basic and translational
studies of osteoarthritis.
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INTRA-ARTICULAR AUGMENTATION OF LUBRICATION WITH SILK
MICROSPHERES
X. Wang, J. Guo, A. Tweed-Kent, A. Dovletoglou, D. Kaplan, A. Bellinger.
Cocoon Biotech, Boston, MA, USA
Purpose: Osteoarthritis of the knee represents a large unmet clinical
need. Deﬁcits in synovial lubrication have been reported in osteo-
arthritis, and several strategies to augment lubrication have shown
preclinical beneﬁt. We hypothesized that augmentation of the boun-
dary lubrication of synovial ﬂuid by intra-articular administration of
long-residence non-inﬂammatory lubricating silk microspheres could
reduce mechanical injury and pain in an osteoarthritis animal model.Methods: Silk microspheres with phospholipid coatings were prepared
by a modiﬁed version of previously published methods. Osteoarthritis
was induced in rats using the surgical instability model consisting of
MCL tear and meniscectomy. One week following injury, affected knees
were intra-articularly administered saline vehicle or silk microspheres
(2.5mg). Serial body weights, knee effusion, gait analysis on Day 14, and
Von Frey secondary allodynia testing on Days -1, 6, and 13 were
measured. Severity of osteoarthritis was assessed by histopathologic
analysis by a trained pathologist on Day 28 after injury.
Results: Silk microspheres with varying size distributions were syn-
thesized and achieved coefﬁcients of friction approaching 0.05 to 0.02.
Intra-articular injection of silk microspheres was well tolerated in rats
with no adverse reactions. Von Frey testing of secondary allodynia 6
days after injection indicated a trend towards a modest but sustained
reduction of osteoarthritic pain.
Conclusions: Intra-articular silk microspheres offer a novel, biologically
inert, non-inﬂammatory, and well tolerated potential therapy for
osteoarthritis. These results motivate further formulation optimization
of silkmicrosphere composition to tune synovial residence, degradation
proﬁle, lubrication properties, and potentially to provide prolonged
delivery of active therapeutics. Augmentation of joint lubrication with
silk microspheres merits further preclinical exploration as a novel
therapy to address the unmet need in osteoarthritis.
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BMI, AGE, RADIOGRAPHIC SEVERITY AND ULTRASOUND GUIDANCE
IMPACT THE RESPONSE TO HYALURONIC ACID INJECTIONS IN KNEE
OSTEOARTHRITIS
E. Wilder, R. Flanagan, E. Strauss, J. Samuels. NYU Langone Hosp. for Joint
Diseases, New York, NY, USA
Purpose:While hyaluronic acid (HA) viscosupplementation has shown
promise in the management of patients with knee osteoarthritis (KOA),
mixed outcome data has led both individual physicians and subspeci-
alty societies to question or eliminate its role in treatment algorithms.
We examined clinical predictors of response to HA injections in a pro-
spective study.
Methods: We screened consecutive patients at HA injections during
routine clinical visits to rheumatology, orthopedics or physiatry at NYU
Langone Medical Center, enrolling those 25 years old with KOA and
pain for 1 month and a visual analog scale pain score 30mm. Base-
line assessments included OA severity by the Kellgren-Lawrence (KL)
scale on knee radiographs within the year prior, a history of comor-
bidities and prior KOA treatment, and patient-reported questionnaires
including the Knee Injury and Osteoarthritis Outcome Score (KOOS),
and the Western Ontario McMasters Universities Osteoarthritis Index
(WOMAC) with a Likert scale calculated from the KOOS. We docu-
mented other variables such as the speciﬁc HA formulation, the ana-
tomic approach, and use of ultrasound guidance. Patients are
completing the questionnaires at 2, 6, 9 and 12 month intervals, but
only continue past 2 months as long as there was still some beneﬁt at
the preceding visit.
Results: Thus far we have screened 194 patients with (ongoing)
enrollment now at 107 (61% female, mean age 58 years ±11, range 27-
84). To date, the cohort’s mean BMI is 30.9 kg/m2±6.6, range 20.9-61.7,
well distributed by BMI subgroup (&lt25, 25-30¼overweight, 30-
35¼obese, and &gt35¼morbidly obese). At baseline, the mean KOOS
pain score (0¼worst, 100¼best) is 47.1 ±17.4, range 0-83.3, and the
WOMAC index (0¼best, 96¼worst) is 45.1±17.8, range 12-96, without a
signiﬁcant difference between the 4 BMI strata. X-rays have been scored
on 85 patients thus far (others are obtaining recent images from other
institutions), but neither the KOOS pain nor WOMAC index at baseline
trends with x-ray severity. Of 102 patients (5 withdrew), 38 have
completed their 2 month followup visits. Patients with a BMI&lt30
(n¼23) responded better than &gt30 (n¼15), both by KOOS pain (þ17.1
vsþ9.2, p¼0.09) andWOMAC index (-15.7 vs -9.2, p¼0.14), with similar
trends across other KOOS and WOMAC scores. The KOOS pain
improvements were better for radiographic grades KL2 and KL3 than
those seen for KL4 (þ 12.8 and þ15.1 vs þ5.9, p¼0.13 for KL 3vs4), as
were the WOMAC index scores (-19.3, -13.7 vs -6.5) The youngest
quartile (ages 37-54) responded better than the middle 2 and the oldest
quartile (ages 70-84) by KOOS pain (þ18.2, þ17.6, þ12.3, þ7.1, p¼0.04
